Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi, Salomon Marcello Stemmer, Howard A. Burris et al. · New England Journal of Medicine · 2016
BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). METHODS: . RESULTS: for superiority). The median duration of follow-up was 15.3 months. After 18 months, the progression-free survival rate was 63.0% (95% confidence interval [CI], 54.6 to 70.3) in the ribociclib group and 42.2% (95% CI, 34.8 to 49.5) in the placebo group. In patients with measurable disease at baseline, the overall response rate was 52.7% and 37.1%, respectively (P<0.001). Common grade 3 or 4 adverse events that were reported in more than 10% of the patients in either group were neutropenia (59.3% in the ribociclib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuation because of adverse events were 7.5% and 2.1%, respectively. CONCLUSIONS: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT01958021 .).
Cited by 2,020 works. doi:10.1056/nejmoa1609709 Open-access PDF
Authors
- Gabriel N. Hortobágyi
- Salomon Marcello Stemmer
- Howard A. Burris
- Yoon Sim Yap
- Gabe S. Sonke
- Shani Paluch–Shimon
- Mario Campone
- Kimberly Blackwell
- Fabrice André
- Eric P. Winer
- Wolfgang Janni
- Sunil Verma
- PierFranco Conte
- Carlos L. Arteaga
- David Cameron
- Katarína Petráková
- Lowell L. Hart
- Cristian Villanueva
- Arlene Chan
- Erik Hugger Jakobsen
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Comprehensive molecular portraits of human breast tumours
- Repeated assessment of results in clinical trials of cancer treatment
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results Database
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer